The HA-1 TCR cell product, composed of CD8 and CD4 T cells engineered with an HA-1 TCR and CD8 coreceptor, is infused into patients after allogeneic stem cell transplantation. The HA-1 TCR T-cell product only attacks the hematopoietic cells of the patient, including the malignant cells, whereas the nonhematopoietic tissue as well as donor-derived hematopoiesis are not attacked.